Secondary Logo

Journal Logo

Research Letters

Immune and virological benefits of 10 years of permanent viral control with antiretroviral therapy

Guihot, Améliea,b; Tubiana, Rolandb,c; Breton, Guillaumed; Marcelin, Anne-Genevièvee; Samri, Assiaa; Assoumou, Lambertc; Goncalves, Emiliaa; Bricaire, Françoisb; Costagliola, Dominiquec; Calvez, Vincente; Rouzioux, Christinef; Autran, Brigittea; Katlama, Christineb,c; Carcelain, Guislainea ALT-ANRS CO-15 study group; DECAMUNE study group

Author Information
doi: 10.1097/QAD.0b013e32833556f3
  • Free


The immunological and virological long-term benefits of a continuous viral suppression with antiretroviral therapy (ART) are still unknown. First, there is still a debate on whether ART allows a CD4 T-cell recovery after more than 5 years [1–4]. Second, ART had been shown to rapidly restore memory T-cell responses to recall or opportunistic antigens [5], but only partially to HIV itself [6–8], and it is not known whether long-term ART can restore such functions. Third, the HIV reservoir in peripheral blood mononuclear cells (PBMCs) had been shown to decrease mostly during the first 3 years of HIV suppression [1], but the effects of long-term ART remain poorly characterized. Finally, it is not known whether long-term ART can allow advanced stage patients to reach a status close to Elite controllers. We studied the impact of a strict viral control throughout 10 years of ART on HIV RNA using ultrasensitive technique, cell-associated HIV DNA, CD4 cell counts and HIV-specific T-cell responses in 16 long-term ART-treated (LTT) progressors. They were compared with short-term ART-treated (STT) patients and Elite HIV controllers.

From the 601 Pitié-Salpêtrière patients treated for 10 years, HIV-1 infected LTT patients were selected on the basis of an undetectable HIV RNA at each time point, with at least one CD4 and HIV RNA measurement/year and more than 20 time points overall. Patients with history of ART interruptions, ‘blips’ of viral replication or immunomodulatory therapies were excluded. Sixteen patients receiving ART for 9.8 (9.3–10.6) years, with a median age of 54 (38–71) years fulfilling these criteria, were included. Before ART initiation, median CD4 cell count was 200 (16–519) cells/μl, median HIV RNA was 5.2 (4.2–6) log copies/ml and five patients had an AIDS-defining clinical condition. Only one patient was HLA B57. No clinical event occurred during their treatment. Thirteen STT-matched patients with similar criteria but with shorter ART duration [median 3.3 (2.3–4.4) years] and similar clinical characteristics at ART initiation (data not shown) were included as controls. In addition, we compared LTT and STT patients to 11 HIV-infected untreated Elite HIV controllers from the French ALT ANRS CO-15 cohort [9] with undetectable HIV RNA at every time point during a 10-year follow-up and a median age of 38 (32–65) years, significantly younger than LTT (P < 0.001, Mann–Whitney test). Plasma HIV-1 RNA levels were determined with the Amplicor-Monitor v1.5 and Cobas AmpliPrep/Cobas Taqman HIV-1 assays (Roche-Diagnostic Systems; threshold 200 and 40 copies/ml, respectively). Ultrasensitive plasma HIV-1 RNA (threshold 1 copy/ml) and HIV-1 cell-associated DNA in PBMCs were quantified [10,11]. Lymphocyte proliferation assays against HIV-p24 were performed on fresh PBMCs using 3H-thymidine and BrdU incorporation assays [12]. ELISpot interferon (IFN)-γ assays with thawed PBMCs used 15 pools of 15-mer overlapping HIV peptides covering gag and RT [13], and responses were expressed as the sum of positive responses to each peptide pool.

In the 16 LTT patients, the CD4 cell counts (678 measurements) showed a continuous increase from a median baseline of 200 (16–519) to 712 (349–1144) cells/μl at year 10 (Fig. 1a) in the following three slopes: the first rapid slope of +191 cellsD4/μl per year (IQR = 47.2) from day 0 to year 1, the second slower slope of +81 cells/μl per year (IQR = 27.1) from years 1 to 3 [5] and the third even slower but still positive slope of +22 cells/μl per year (IQR = 9) between years 3 and 10. These three positive slopes significantly differed from zero at each time point (P < 0.02, Wilcoxon test). At the time of analysis, the CD4 cell counts did not differ between STT and Elite HIV controllers patients (Mann–Whitney test): 560 (124–1338) and 715 (559–902) cells/μl, respectively. HIV plasma viral loads were below 1 copy/ml in 14/16 LTT and 8/13 STT patients, whereas they were detectable in 9/11 Elite HIV controllers [median 46 (1–530) copies/ml] (Fig. 1b). The median cell-associated HIV DNA in the 16 LTT patients was 157 (5–632) copies/106 cells, lower but not significantly lower than that in the eight STT patients tested [353 (126–2240) copies/106 cells] (P = 0.05, Mann–Whitney test) but significantly higher than that in the Elite HIV controllers [50 (20–170) copies/106 cells] (P < 0.01) (Fig. 1c). Stronger proliferative T-cell responses to HIV-p24 were detected in LTT with higher stimulation indexes [median 12 (2–80)] than in both STT [median 3 (1–53)] (P = 0.03) and Elite HIV controllers [median 3 (1–74)] (P = 0.13, Mann–Whitney test) (Fig. 1d). These responses were mediated by CD4+ T cells as shown in the BrdU proliferation assay for seven LTT patients tested (data not shown). HIV-specific T cells producing IFN-γ ex vivo were significantly lower in LTT than in Elite HIV controllers [median 227 (0–4067) and 2594 (160–11 167) spot-forming cells/106 PBMCs, P < 0.01] (Fig. 1e).

Fig. 1
Fig. 1:
CD4 cell counts changes overtime, ultrasensitive detection of plasma HIV RNA, HIV-cell associated DNA (c) and HIV-specific T -cell responses after 10 years of HIV control with antiretroviral therapy. (a) Means and interquartile ranges of CD4 cell counts after each year of antiretroviral therapy (ART) in 16 long-term treated (LTT) patients (dotted line). The slopes of CD4 increases were calculated according to a linear model regression (straight line). A Wilcoxon nonparametric test was used to compare slopes. (b) Ultrasensitive plasma HIV RNA in 16 LTTs, compared with 13 short-term treated (STT), patients and 11 HIV Elite controllers (ECs). The threshold of detection was 1 copy/ml. (c) Cell-associated HIV DNA quantified by real-time PCR in 16 LTTs, nine STTs patients and 11 ECs. Results are expressed as the number of copies/106 peripheral blood mononuclear cells (PBMCs). (d) Lymphoproliferative responses to p24 recombinant protein in a 3H-thymidine incorporation assay in 15 LTT patients, compared to 13 STT patients and 11 HIV ECs. Results are shown as a stimulation index (SI). (e) T-cell responses to HIV 15-mer peptides covering gag and RT in ELISpot interferon-γ assays in 14 LTT, eight STT patients and eight HIV ECs. Individual sums of positive responses to HIV peptides pools are shown. Results are expressed as spot-forming cells (SFCs)/106 PBMCs. Positive threshold was 50 SFCs/106 PBMCs. A nonparametric Mann–Whitney correlation test was used to compare values between groups.

This study reports the benefits of 10 years of continuous viral suppression with ART on CD4 cell counts, HIV-specific T-cell responses and HIV control and reservoir. Contrasting with the finding of previous studies reporting that CD4 cell counts plateau after 3–5 years of ART [2–4,14,15], our study showed that the CD4 cell counts continue to increase 10 years after ART initiation, despite low CD4 nadirs or an advanced age in some patients. This might reflect the continuous virological control and the lack of viral blips in these highly selected patients.

Immune benefits of long-term treatments were also assessed by the restoration of stronger memory CD4+ T-cell responses to HIV-p24 than in STT, although both groups showed similar standard predictors of immune restoration, such as age, CD4 cell count nadir and plasma HIV RNA control [15–18]. Those memory responses reached levels comparable to those observed in Elite HIV controllers. These data suggest that a prolonged virological control with ART allows a continuous restoration process of HIV-specific central memory T cells. In contrast, this long-term virus control puts at rest the anti-HIV T-cell response producing IFN-γ ex vivo, which should correspond to effector or effector/memory T cells. This phenomenon reflects the prolonged clonal contraction induced by the sustained very low levels of HIV antigen stimulation in vivo. Finally, the trend toward lower plasma HIV RNA and HIV DNA in LTT than in STT suggests that HIV reservoirs can continue to decrease after 5 years of ART, although their HIV reservoirs remain higher than in untreated Elite HIV controllers. The substantial residual HIV replication in Elite HIV controllers reflects the absence of ART.

In conclusion, this sustained control of HIV over 10 years of continuous ART in advanced stage progressors induces the residual HIV replication down to undetectable levels and affects the HIV reservoirs. This allows an immune reconstitution process with near to normal CD4 cell counts and strong HIV-specific memory T cells comparable to those of Elite HIV controllers. The positive CD4 cell count slope observed until the 10th year of treatment disfavors the hypothesis that the immune system cannot achieve normalization. These findings suggest the importance of promoting continuous viral suppression with ART to achieve better immunological and virological outcomes as the duration of viral control increases.


This study was supported by the AP-HP Centre d'Investigations Biomédicales (CIB) of the Pitié-Salpêtrière Hospital and by the French Agency for AIDS Research (ANRS). The authors thank the following decamune patient's physicians: Pascal Astagneau, Philippe Bossi, Martin Danis, Luc Paris and Marc Antoine Valantin.

The DECAMUNE study group is composed of Brigitte Autran, Guillaume Breton, Vincent Calvez, Guislaine Carcelain, Dominique Costagliola, Amélie Guihot, Christine Katlama, Anne-Geneviève Marcelin, Roland Tubiana.

The ALT-ANRS CO-15 group is composed of Henri Agut, Jean-Pierre Clauvel, Dominique Costagliola, Patrice Debré, Christine Rouzioux, Didier Sicard, Ioannis Theodorou, Brigitte Autran.

This study was presented during the 15th Conference on Retroviruses and Opportunistic Infections, February 2008, Boston, MA, USA (Abstract A-190).


1. Viard JP, Burgard M, Hubert JB, Aaron L, Rabian C, Pertuiset N, et al. Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level. AIDS 2004; 18:45–49.
2. Moore RD, Keruly JC. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis 2007; 44:441–446.
3. Le Moing V, Thiebaut R, Chene G, Sobel A, Massip P, Collin F, et al. Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/ml during treatment with antiretroviral drugs. HIV Med 2007; 8:156–163.
4. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362:22–29.
5. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997; 277:112–116.
6. Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H, Autran B. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998; 351:1682–1686.
7. Angel JB, Parato KG, Kumar A, Kravcik S, Badley AD, Fex C, et al. Progressive human immunodeficiency virus-specific immune recovery with prolonged viral suppression. J Infect Dis 2001; 183:546–554.
8. Lange CG, Lederman MM, Madero JS, Medvik K, Asaad R, Pacheko C, et al. Impact of suppression of viral replication by highly active antiretroviral therapy on immune function and phenotype in chronic HIV-1 infection. J Acquir Immune Defic Syndr 2002; 30:33–40.
9. Candotti D, Costagliola D, Joberty C, Bonduelle O, Rouzioux C, Autran B, Agut H. Status of long-term asymptomatic HIV-1 infection correlates with viral load but not with virus replication properties and cell tropism. French ALT Study Group. J Med Virol 1999; 58:256–263.
10. Yerly S, Kaiser L, Perneger TV, Cone RW, Opravil M, Chave JP, et al. Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia. The Swiss HIV Cohort Study. AIDS 2000; 14:243–249.
11. Rouzioux C, Hubert JB, Burgard M, Deveau C, Goujard C, Bary M, et al. Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4+ T cell counts. J Infect Dis 2005; 192:46–55.
12. Combadiere B, Boissonnas A, Carcelain G, Lefranc E, Samri A, Bricaire F, et al. Distinct time effects of vaccination on long-term proliferative and IFN-gamma-producing T cell memory to smallpox in humans. J Exp Med 2004; 199:1585–1593.
13. Samri A, Durier C, Urrutia A, Sanchez I, Gahery-Segard H, Imbart S, et al. Evaluation of the interlaboratory concordance in quantification of human immunodeficiency virus-specific T cells with a gamma interferon enzyme-linked immunospot assay. Clin Vaccine Immunol 2006; 13:684–697.
14. Gras L, Kesselring AM, Griffin JT, van Sighem AI, Fraser C, Ghani AC, et al. CD4 cell counts of 800 cells/μl or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/μl or greater. J Acquir Immune Defic Syndr 2007; 45:183–192.
15. Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/μl in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis 2005; 41:361–372.
16. Dragsted UB, Mocroft A, Vella S, Viard JP, Hansen AB, Panos G, et al. Predictors of immunological failure after initial response to highly active antiretroviral therapy in HIV-1-infected adults: a EuroSIDA study. J Infect Dis 2004; 190:148–155.
17. Wood E, Hogg RS, Yip B, Quercia R, Harrigan PR, O'Shaughnessy MV, Montaner JS. Higher baseline levels of plasma human immunodeficiency virus type 1 RNA are associated with increased mortality after initiation of triple-drug antiretroviral therapy. J Infect Dis 2003; 188:1421–1425.
18. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119–129.
© 2010 Lippincott Williams & Wilkins, Inc.